Hypothesis

Aging‑related depletion of pericellular hyaluronic acid (HA) microdomains at the thyroarytenoid (TA) muscle–lamina propria junction impairs CD44‑mediated mechanotransduction, leading to nuclear exclusion of YAP/TAZ, a shift toward slow‑twitch myosin heavy chain isoforms, and reduced satellite cell activation. This molecular cascade explains the observed >20% TA volume loss and predicts poor durability of injectable augmentation because the biomechanical milieu that supports muscle‑ECM reciprocity is absent.

Mechanistic Rationale

1. HA microdomains normally bind CD44 on fibroblasts and satellite cells, transmitting tissue‑tension signals that activate the Hippo‑effector YAP/TAZ pathway (see [https://pmc.ncbi.nlm.nih.gov/articles/PMC3522788/] for TA regeneration indices).
2. In aged lamina propria, loss of high‑molecular‑weight HA and increased HA‑fragment accumulation shift CD44 signaling toward a pro‑inflammatory, RhoA/ROCK‑biased state, promoting YAP cytoplasmic retention.
3. YAP/TAZ nuclear activity drives transcription of proliferative genes (e.g., Cyclin D1, Myc) and maintains a fast‑twitch fiber program via Myf5/Myod upregulation; its suppression favors slow‑twitch (Myh7) expression and attenuates satellite cell proliferative capacity.
4. Consequently, the TA undergoes atrophy, fiber‑type transition, and reduced regenerative potential, which volumetric MRI captures as volume loss but fiber‑type shifts remain uncharacterized in humans.
5. Injectable biomaterials (e.g., hyaluronic acid fillers) rely on host‑derived HA to integrate and provide a resistive scaffold; without endogenous HA‑CD44‑YAP signaling, the graft fails to stimulate mechanoresponsive remodeling, leading to variable reinjection timing.

Testable Predictions

• Prediction 1: Older patients with presbyphonia will show a statistically significant reduction in pericellular HA‑CD44 colocalization (measured by proximity ligation assay) compared with age‑matched controls, correlating with lower YAP nuclear staining in TA satellite cells (r > 0.5, p < 0.01).
• Prediction 2: The degree of HA‑CD44 loss will predict the magnitude of fast‑to‑slow fiber‑type shift (quantified by Myh2/Myh7 ratio from single‑fiber immunohistochemistry) and explain >30% of TA variance in volumetric MRI beyond age alone.
• Prediction 3: In a prospective cohort receiving calcium‑hydroxyapatite or HA‑based injection augmentation, individuals with low baseline HA‑CD44‑YAP activity will exhibit <10‑point improvement in Voice Handicap Index (VHI) and <0.2 increase in glottal closure quotient at 6 months, whereas those with high activity will achieve ≥15‑point VHI gain.

Experimental Approach

• Obtain lateral vocal fold biopsies from patients undergoing microlaryngoscopy for suspected presbyphonia (n = 30) and controls (n = 15). Perform multiplex immunofluorescence for HA (using HA‑binding protein), CD44, YAP, Pax7 (satellite cell marker), and myosin heavy chain isoforms.
• Quantify pericellular HA‑CD44 proximity (<40 nm) via Duolink PLA; measure nuclear YAP fraction in Pax7+ cells.
• Correlate histology with pre‑operative MRI volumetrics, fiber‑type orientation (derived from diffusion tensor imaging), and postoperative voice outcomes after standardized augmentation.
• Use multivariate regression to test whether HA‑CD44‑YAP metrics add predictive value beyond age and baseline VHI.

Falsifiability

If HA‑CD44 colocalization and YAP nuclear localization show no difference between presbyphonic and control tissues, or if these markers fail to correlate with fiber‑type shifts or augmentation outcomes, the hypothesis is refuted. Conversely, a strong, mechanistically linked association would support the model and suggest that restoring pericellular HA (e.g., via HA‑secreting fibroblast grafts) could augment regeneration and improve treatment durability.

Implications

This hypothesis bridges the gap between ECM composition (specifically HA microdomain organization) and muscle fiber dynamics, offering a biomarker‑driven pathway to personalize augmentation strategies and to develop biologics that target the HA‑CD44‑YAP axis in the aging vocal fold.

Key references: [https://pmc.ncbi.nlm.nih.gov/articles/PMC3522788/], [https://pubs.asha.org/doi/10.1044/2023_AJSLP-23-00143], [https://pmc.ncbi.nlm.nih.gov/articles/PMC11005858/], [https://pmc.ncbi.nlm.nih.gov/articles/PMC12677544/], [https://pmc.ncbi.nlm.nih.gov/articles/PMC12326623/]